AstraZeneca pays 666% premium to buy genomic medicine biotech

AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio Therapeutics to secure technology platforms and expertise in their use.